AEON Biopharma CFO files initial insider ownership

AEON Biopharma, Inc. filed an initial insider ownership report for its Chief Financial Officer, John Bencich.

Accepted by SEC EDGAR 04/03/2026 - 06:22 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

AEON Biopharma, Inc. filed an initial insider ownership report for its Chief Financial Officer, John Bencich. This filing is a Form 3, which serves as the starting disclosure of his beneficial ownership in AEON as an officer. The report does not list any specific transactions or share movements.

Key Terms

Form 3, beneficial ownership, Chief Financial Officer

3 terms

Form 3 regulatory

"This filing is a Form 3, which serves as the starting disclosure"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"serves as the starting disclosure of his beneficial ownership in AEON"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Chief Financial Officer financial

"filed an initial insider ownership report for its Chief Financial Officer, John Bencich"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the AEON Biopharma (AEON) Form 3 filing report for John Bencich?

The Form 3 filing reports that John Bencich serves as Chief Financial Officer of AEON Biopharma. It functions as his initial statement of beneficial ownership as an officer, without detailing any specific stock purchases, sales, or other insider transactions in the company’s securities.

Does the AEON Biopharma (AEON) Form 3 show any insider buying or selling?

No, the Form 3 does not show any insider buying or selling activity. The transaction summary lists zero buys, zero sells, zero derivative exercises, and no gifts or restructurings, indicating this filing is purely an initial ownership disclosure without trade activity.

Who is the insider named in AEON Biopharma’s (AEON) latest Form 3 filing?

The insider named is John Bencich, who is identified as the Chief Financial Officer of AEON Biopharma. The filing confirms his officer status and role but does not attach any specific share transactions or derivative holdings within this particular disclosure.

Why is AEON Biopharma (AEON) filing a Form 3 for its Chief Financial Officer?

AEON Biopharma is filing a Form 3 because John Bencich, as Chief Financial Officer, is a reporting person under SEC rules. Form 3 serves as his initial statement of beneficial ownership in the company’s securities after he becomes an officer subject to these reporting requirements.

Does the AEON Biopharma (AEON) Form 3 include any derivative securities information?

No, the filing shows an empty derivative summary and a derivative transaction count of zero. This means the disclosure does not list any options, warrants, or other derivative securities for John Bencich in this initial ownership statement, based on the provided data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bencich John

(Last) (First) (Middle)

C/O AEON BIOPHARMA, INC.

5 PARK PLAZA, SUITE 1750

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2026

3. Issuer Name and Ticker or Trading Symbol
AEON Biopharma, Inc. [ AEON ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Alexander Wilson, Attorney-in-Fact for John Bencich	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)